Aptose BiosciencesAPTO
About: Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
Employees: 36
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 26 [Q3] → 26 (+0) [Q4]
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
11.14% less ownership
Funds ownership: 17.84% [Q3] → 6.7% (-11.14%) [Q4]
32% less capital invested
Capital invested by funds: $1.33M [Q3] → $897K (-$431K) [Q4]
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Joseph Pantginis 18% 1-year accuracy 73 / 408 met price target | 1,526%upside $60 | Buy Reiterated | 12 Feb 2025 |
Financial journalist opinion
Based on 3 articles about APTO published over the past 30 days









